Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Funding Agency:
National Institutes of Health

NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

NIAID is therefore offering Competitive Revisions to active NIAID grants addressing research objectives described below.

Applications in response to this NOSI must be submitted using the following targeted funding opportunity:

  • PA-20-135; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
  • The funding instrument, or activity code, will be the same as the parent award. All activity codes of currently funded NIAID grants are eligible.
  • Please note: NOT-AI-20-034 is specific for PA-20-135. NIH grantees seeking additional funds for research responsive to the SARS-CoV-2/COVID-19 outbreak that falls within the scope of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements FOA (https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html).

Applications will be accepted on a rolling basis 03/25/2020 from 03/25/2021 through 5:00 PM local time of the applicant organization. An application submitted in response to this NOSI that is received on 03/25/2021 or later, will be withdrawn.

Agency Website

Areas of Interest

In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:

  • Studies to identify optimal in vitroculture requirements and conditions;
  • Development of reagents and assays for virus characterization;
  • Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
  • Studies to identify viral epitopes critical for binding neutralization;
  • Studies to examine virus stability and persistence;
  • Production of molecular clones of SARS-CoV-2, reporter viruses and recombinant viral proteins;
  • Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;
  • Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;
  • Virologic and serologic surveillance studies of the distribution and natural history of SARS-CoV-2 viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;
  • Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2;
  • Development of SARS-COV-2 therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of SARS-CoV-2 antiviral activity of existing or candidate therapeutics initially developed for other indications;
  • Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and
  • Development of SARS-CoV-2 vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

March 24, 2021